ArticlePsychopharmacology2026
The anxiolytic effects of quetiapine and lithium and anxiety as a moderator of the antidepressant effect: a secondary analysis of the lithium versus quetiapine in depression (LQD)trial.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
rationaleLQD was an open-label randomised trial comparing lithium versus quetiapine augmentation of antidepressants in treatment-resistant depression (TRD). In the primary analysis, quetiapine was more effective at reducing depressive symptoms.
objectivesConduct a secondary analysis of LQD to examine anxiolysis of Quetiapine compared to Lithium and examine baseline anxiety as a moderator of antidepressant effects.
methodsUsing linear mixed-models we examined the difference between lithium and quetiapine in anxiety (GAD-7) at 8, 26 and 52 weeks. We modified the main trial’s linear mixed-model with an interaction term for baseline anxiety to estimate the differences in area under the curve (AUC) between treatments for three baseline anxiety levels across the 52 weeks.
resultsThere was little difference between the anxiolysis of quetiapine compared to lithium at 8 (-0.07, p = 0.92), 26 (-0.71, p = 0.30) or 52 weeks (-0.05, p = 0.95). For those with severe baseline anxiety, participants taking quetiapine showed a greater reduction in depressive symptoms than lithium (AUC − 111.6 (95% CI -5.6 to -217.6), p = 0.039). For those with moderate (AUC − 79.7 (95% CI 34.8 to -194.2), p = 0.17) and mild/absent baseline anxiety (AUC 29.7 (95% CI 73.4 to -132.8), p = 0.57), the difference was not statistically significant.
conclusionsWe did not identify a difference between quetiapine and lithium in anxiolytic effects. The superior antidepressant effects of quetiapine were more apparent in those with higher baseline anxiety and may not be present in those with mild or absent baseline anxiety. Further exploration by pooled analyses of prior trial data is warranted.
Indexed as
Identifiers
41762225What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.